RANKL/TNFSF11 蛋白, Cynomolgus (HEK293, Fc)

RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Human (HEK293, hFc) is a recombinant human RANKL (G63-D244) with N-terminal hFc tag, which is produced in HEK293^[1][2].

RANKL (TNFSF11) 属于 TNF 家族。RANKL 是一种 II 型跨膜蛋白，是 NF-κB (RANK) 配体的受体激活剂。RANKL 是 RANK 的激活剂。RANKL 与 RANK 结合，诱导单核细胞/巨噬细胞谱系细胞分化为破骨细胞，并导致破骨细胞前体成熟。在骨组织中，RANKL 由成骨细胞、骨细胞和免疫细胞表达，尤其是在成骨细胞和骨细胞中表达^[1]。RANKL 也由 T 细胞表达，可增加树突状细胞的增殖和存活^[2]。
RANKL 由胞质结构域 (1-47)、螺旋结构域 (48-68) 和胞外结构域 (69-317)。当基质金属蛋白酶（MMP3 或 7）和 ADAM^[1][3] 等酶裂解时，可溶性链 (140-317) 被释放。
RANKL 对于破骨细胞成熟、骨建模和骨重塑以及淋巴结 (LN) 的发育至关重要^[1]。

RANKL (human, -5 ng/mL, 24 h) stimulates migration of a clear cell RCC cell line, Caki-1^[4].
RANKL (human, 24 h) stimulates PAa cell migration and invasion^[5].

RANKL (human, .4 or 2 mg/kg/day, s.c.) induces high bone turnover and decreases bone volume, density, and strength in C57BL/6J female mice^[6].

The bioactivity was determined by measuring the ability of RANKL to induce TRAP activity in RAW 264.7 cells. The ED₅₀ for this effect is ≤10 ng/mL, corresponding to a specific activity is ≥1×10⁵ U/mg

• 
  The bioactivity was determined by measuring the ability of RANKL to induce TRAP activity in RAW264.7 cells. The ED₅₀ for this effect is 8.028 ng/mL， corresponding to a specific activity is 1.246×10⁵ U/mg.

Cynomolgus

HEK293

N-hFc

A0A7N9DBU4 (G136-D317)

/

GSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATNIPTGSHKVSLSSWYHDRGWAKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMVYVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISVEVSNPSLLDPDQDATYFGAFKVRDID

Approximately 56 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Ono T, et al. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen. 2020 Feb 7;40:2.  [Content Brief]

  [2]. Li B, et al. Roles of the RANKL-RANK Axis in Immunity-Implications for Pathogenesis and Treatment of Bone Metastasis. Front Immunol. 2022 Mar 21;13:824117.  [Content Brief]

  [3]. Tobeiha M, et al. RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling. Biomed Res Int. 2020 Feb 19;2020:6910312.  [Content Brief]

  [4]. Mikami S, et al. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol. 2009 Aug;218(4):530-9.  [Content Brief]

  [5]. Peng X, et al. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. PLoS One. 2013;8(3):e58361.  [Content Brief]

  [6]. Lloyd SA, et al. Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. Calcif Tissue Int. 2008 May;82(5):361-72.  [Content Brief]